Last reviewed · How we verify
Diginorgin (digitalin)
Diginorgin (generic name: digitalin) is a drug. It is currently in unknown development.
Digitalin works by inhibiting the sodium-potassium pump in cardiac cells, leading to increased intracellular calcium levels and subsequent contraction.
Diginorgin, also known as digitalin, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. As a result, there is limited information available on its safety profile and generic availability. Further research is needed to fully understand the properties and potential uses of diginorgin.
At a glance
| Generic name | digitalin |
|---|---|
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Imagine your heart cells have a special pump that helps them relax and contract. Digitalin blocks this pump, causing the cells to take in more calcium, which makes them contract more strongly. This can help the heart beat more efficiently, but it can also have negative effects if not used carefully.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diginorgin CI brief — competitive landscape report
- Diginorgin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Diginorgin
What is Diginorgin?
How does Diginorgin work?
What is the generic name of Diginorgin?
What development phase is Diginorgin in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing